- An advanced Affinity Selection Mass Spectrometry for Membrane Proteins -
Our cutting-edge technology is a breakthrough in Affinity Selection Mass Spectrometry (ASMS), extending its application from soluble proteins to membrane proteins without the need for solubilization.
This high-throughput method is versatile, accommodating any target type, and streamlines the screening process. Uniquely, our approach can be applied to orphan receptors, ion channels, transporters, and target RNAs, even those with unknown biological activity.
By utilizing a single, streamlined method across all target types, we can obtain highly specific binders for each target.
Our extensive screening campaigns have built a robust binder collection, including specific binders for numerous GPCRs, SLC transporters, and ion channels. Our technology excels in identifying ligands for protein degraders as silent binders.
Impressive Achievements
To date, we have successfully identified binders for:
• 200 GPCRs, including orphan GPCRs
• 150 SLC transporters
Explore the potential of our advanced ASMS technology to revolutionize your research and drug discovery projects.
Binder Collection (database)
Binder database for SLC transporterWe have conducted screenings on several SLC transporters and obtained binding compounds for 154 of them. SLC6A9 is one of these transporters. The binders were tested for their ability to inhibit Glycine uptake in cells. In the graph, the vertical axis represents binding, while the horizontal axis shows the inhibition of Glycine uptake in cells. A very clear correlation is observed.
Binder database for GPCRWe have conducted screenings on several GPCRs and obtained binding compounds for 197 of them. GPR87 is one of these GPCRs. The binders obtained were then tested using a Ca influx assay. In the graph, the vertical axis represents binding, while the horizontal axis shows the EC50 values from the Ca influx assay. We identified one compound as an antagonist, and the rest were agonists.
We are implementing a strategy of generating hits for each target class and selecting promising pipelines from them.
We are constructing binder collections using our protein library and compound library.
We have already had binders of some SLC transporters and GPCRs as pipelines in discovery stage.
Target identification
For compounds with unknown target proteins, we use our proprietary technology to screen for binding interactions with proteins expressed from our library of approximately 17,000 cDNA clones.
